Aurinia Pharmaceuticals annual net debt
2019
2020
2021
2022
2023
2024
2025
Aurinia Pharmaceuticals Net Debt Growth & History (AUPH)
Aurinia Pharmaceuticals's net debt was −$5.3M for fiscal 2025.
View full Aurinia Pharmaceuticals company overviewAurinia Pharmaceuticals annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$5.3M | −$1.3M | — |
| 2024 | 2024-12-31 | −$4.0M | −$52.9M | — |
| 2023 | 2023-12-31 | $48.9M | $134.9M | — |
| 2022 | 2022-12-31 | −$86.0M | $136.9M | — |
| 2021 | 2021-12-31 | −$222.9M | $41.0M | — |
| 2020 | 2020-12-31 | −$263.9M | $42.1M | — |
| 2019 | 2019-12-31 | −$306.0M | — | — |
Aurinia Pharmaceuticals quarterly net debt
Q4.19
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$115.6M | −$144.5M | — |
| Q1 2026 | 2026-03-31 | $27.9M | $16.1M | +136.42% |
| Q4 2025 | 2025-12-31 | −$5.3M | −$1.3M | — |
| Q3 2025 | 2025-09-30 | $5.3M | −$45.9M | −89.61% |
| Q2 2025 | 2025-06-30 | $28.9M | −$23.8M | −45.15% |
| Q1 2025 | 2025-03-31 | $11.8M | −$12.8M | −52.09% |
| Q4 2024 | 2024-12-31 | −$4.0M | −$52.9M | — |
| Q3 2024 | 2024-09-30 | $51.2M | $3.6M | +7.48% |
| Q2 2024 | 2024-06-30 | $52.7M | $32.9M | +166.02% |
| Q1 2024 | 2024-03-31 | $24.6M | $105.0M | — |
| Q4 2023 | 2023-12-31 | $48.9M | $134.9M | — |
| Q3 2023 | 2023-09-30 | $47.7M | $124.8M | — |
| Q2 2023 | 2023-06-30 | $19.8M | $162.8M | — |
| Q1 2023 | 2023-03-31 | −$80.4M | $42.7M | — |
| Q4 2022 | 2022-12-31 | −$86.0M | $136.9M | — |
| Q3 2022 | 2022-09-30 | −$77.2M | −$28.5M | — |
| Q2 2022 | 2022-06-30 | −$143.0M | −$30.4M | — |
| Q1 2022 | 2022-03-31 | −$123.1M | $24.6M | — |
| Q4 2021 | 2021-12-31 | −$222.9M | $41.0M | — |
| Q3 2021 | 2021-09-30 | −$48.7M | — | — |
| Q2 2021 | 2021-06-30 | −$112.6M | — | — |
| Q1 2021 | 2021-03-31 | −$147.7M | — | — |
| Q4 2020 | 2020-12-31 | −$263.9M | $42.1M | — |
| Q4 2019 | 2019-12-31 | −$306.0M | — | — |
Aurinia Pharmaceuticals net debt trends
Over the last five fiscal years, Aurinia Pharmaceuticals's net debt increased from −$263.9M to −$5.3M, a change of $258.6M. The latest reported quarter, Q2 2026, shows −$115.6M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Aurinia Pharmaceuticals source filings ↗